Print this page    •   Back to Web version of article

International News
Bristol-Myers Squibb Shares Intellectual Property Rights of Reyataz With Medicines Patent Pool

December 12, 2013

"Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries," Reuters reports. The licensing deal between the Medicines Patent Pool (MPP) and Bristol "will enable generic drug firms around the world to produce affordable versions of atazanavir, [sold] under the brand name Reyataz, and to combine it with other medicines to make treatment easier," the news agency notes (Hirschler, 12/12). "This is the MPP's first agreement covering a [WHO]-preferred second-line therapy. The WHO estimates there will be over one million people on second-line treatment by 2016, and many more will need access to these therapies," according to an MPP press release (12/12).

Back to other news for December 2013


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.




This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/73488/bristol-myers-squibb-shares-intellectual-property-.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.